---

TRAUMATIC PERFORATION OF THE TYMPANIC MEMBRANE

Comprehensive Management — 50 Marks Answer

(Scott-Brown | Cummings | Stell & Maran | Zakir Hussain | Dhingra | Hazarika | Recent Advances)

---

1. INTRODUCTION

---

2. APPLIED ANATOMY

┌─────────────────────────────────────────────────────────────┐
│              TYMPANIC MEMBRANE — ANATOMY                    │
│                                                             │
│   Pars Flaccida (Shrapnell's membrane)                      │
│         ↑                                                   │
│   ┌─────┴──────────────────────────────────┐                │
│   │           PARS TENSA                   │                │
│   │  ┌──────────────────────────────────┐  │                │
│   │  │  Anterior  │  Posterior          │  │                │
│   │  │  Superior  │  Superior           │  │                │
│   │  ├────────────┼────────────────────-┤  │                │
│   │  │  Anterior  │  Posterior          │  │                │
│   │  │  Inferior  │  Inferior           │  │                │
│   │  └──────────────────────────────────┘  │                │
│   │              Umbo (center)             │                │
│   │              Cone of Light             │                │
│   └────────────────────────────────────────┘                │
│                                                             │
│  Layers: Squamous epithelium → Fibrous layer → Mucosa       │
│  Blood supply: Deep auricular artery (outer)                │
│                Anterior tympanic artery (inner)             │
│  Nerve supply: Auriculotemporal + Arnold's nerve            │
└─────────────────────────────────────────────────────────────┘

• Pars tensa: 85% of TM — site of most traumatic perforations
• Pars flaccida: 15%, lacks fibrous layer, rarely traumatically perforated
• Annulus fibrosus: Peripheral fibrocartilaginous ring anchoring TM to tympanic sulcus

---

3. ETIOLOGY AND CLASSIFICATION OF TRAUMATIC PERFORATION

3.1 Causes (Dhingra — Diseases of ENT, 8th Ed.)

3.2 Pathomechanism

• Compression type (indirect/blast): Sudden increase in EAC pressure → TM unable to equilibrate → rupture, typically in anterior inferior quadrant (the thinnest area)
• Laceration type (direct): Sharp instrument perforates TM → ragged, irregular edges; may involve ossicles

3.3 Classification by Site (Scott-Brown's Otolaryngology, 8th Ed.)

┌───────────────────────────────────────────────┐
│         CLASSIFICATION OF PERFORATIONS         │
│                                               │
│  By LOCATION:                                 │
│  • Central — within pars tensa, rim of        │
│    annulus intact (SAFE)                      │
│  • Marginal — reaches tympanic annulus        │
│    (risk of cholesteatoma)                    │
│  • Attic (Pars flaccida) — dangerous          │
│                                               │
│  By SIZE:                                     │
│  • Small: <25% of TM area                    │
│  • Medium: 25–50%                             │
│  • Large: 50–75%                              │
│  • Subtotal: >75%, annulus intact             │
│  • Total: entire TM lost                      │
│                                               │
│  By APPEARANCE (Acute):                       │
│  • Slit-like, stellate, or crescentic         │
│  • Edges: fresh (red) vs. rolled (chronic)    │
└───────────────────────────────────────────────┘

---

4. CLINICAL FEATURES

4.1 Symptoms

4.2 Signs

• Otoscopy: Irregular rent in TM (acute — red edges, fresh blood); rolled white epithelial edges in healing phase
• Rinne's test: Negative (BC > AC) — conductive hearing loss
• Weber's test: Lateralises to the affected ear
• Pure Tone Audiogram: Air-bone gap (typically 20–40 dB) in low frequencies
• Tuning fork tests: 256 Hz and 512 Hz
• Tympanometry: Type B (flat) curve

---

5. INVESTIGATIONS

┌────────────────────────────────────────────────────────────┐
│            INVESTIGATIONS — ALGORITHMIC APPROACH           │
├────────────────────────────────────────────────────────────┤
│  1. Otoscopy (diagnostic)                                  │
│     ↓                                                      │
│  2. Pure Tone Audiogram (PTA)                              │
│     - Air-bone gap quantification                          │
│     - SNHL component → suspect inner ear injury            │
│     ↓                                                      │
│  3. Tympanometry                                           │
│     - Type B: flat (perforation/fluid)                     │
│     - Type Ad: ossicular discontinuity                     │
│     ↓                                                      │
│  4. HRCT Temporal Bone                                     │
│     - Indicated if: SNHL, vertigo, facial palsy,          │
│       suspected ossicular disruption, blast/fracture       │
│     - Assess: ossicular chain, tegmen, labyrinth           │
│     ↓                                                      │
│  5. Speech Audiometry / Impedance audiometry              │
│  6. Vestibular function tests (if vertigo present)         │
│     - ENG/VNG, VEMP                                        │
│  7. MRI (if intracranial extension suspected)              │
└────────────────────────────────────────────────────────────┘

---

6. MANAGEMENT

OVERVIEW FLOWCHART

┌────────────────────────────────────────────────────────────────────────┐
│              TRAUMATIC TM PERFORATION — MANAGEMENT ALGORITHM           │
└────────────────────────────────────────────────────────────────────────┘
                              │
                              ▼
              ┌───── INITIAL ASSESSMENT ─────┐
              │  History + Otoscopy + PTA     │
              │  Check: size, site, infection │
              │  vertigo, SNHL, facial nerve  │
              └───────────────┬───────────────┘
                              │
              ┌───────────────▼───────────────┐
              │   EMERGENCY FEATURES?          │
              │   • Profound SNHL              │
              │   • Perilymph fistula          │
              │   • Facial nerve palsy         │
              │   • Temporal bone fracture     │
              └──────┬────────────────┬────────┘
                     │YES             │NO
                     ▼               ▼
           ┌──────────────┐   ┌─────────────────────┐
           │  URGENT REFER │   │   CONSERVATIVE Rx    │
           │  to Neurotol. │   │  (Watchful waiting)  │
           │  + HRCT TB    │   └──────────┬───────────┘
           └──────────────┘              │
                                         ▼
                          ┌──────────────────────────┐
                          │  REVIEW at 3 MONTHS       │
                          │  Has it healed?           │
                          └──────┬──────────┬─────────┘
                                 │YES       │NO
                                 ▼          ▼
                          ┌──────────┐ ┌──────────────────────┐
                          │ DISCHARGE│ │  SURGICAL REPAIR      │
                          │  with    │ │  Myringoplasty/       │
                          │  PTA     │ │  Tympanoplasty        │
                          └──────────┘ └──────────────────────┘

---

6.1 CONSERVATIVE MANAGEMENT

A. Immediate First Aid

1. Do NOT irrigate the ear — risk of introducing infection into middle ear
2. Keep the ear dry — cotton wool plug lightly placed at meatus (NOT packed tightly)
3. No ear drops unless infected — especially avoid aminoglycoside drops (ototoxic with open TM)
4. Reassurance — most small traumatic perforations heal spontaneously

B. Medical Management

C. Observation Period

• 85–90% of traumatic perforations <50% size heal spontaneously within 4–8 weeks (Scott-Brown, 8th Ed.)
• Bailey & Love (28th Ed., p. 777): "Traumatic perforations of the tympanic membrane usually heal spontaneously but explosive and welding injuries do not."
• Exceptions with poor spontaneous healing:
  • Blast/explosion injuries
  • Welding spark injuries (thermal coagulation of edges prevents epithelial migration)
  • Large perforations (>50%)
  • Infections complicating perforation
  • Marginal perforations

---

6.2 OFFICE PROCEDURES (NON-SURGICAL REPAIR)

A. Chemical Cauterisation / Edge Freshening

• Applied to rolled, epithelialised edges to stimulate healing
• Agent: 50% Trichloroacetic acid (TCA) applied with fine applicator to edge only
• Mechanism: Destroys epithelium migrating across perforation, stimulates fibrous regeneration
• Indication: Small perforations with epithelialised edges after 6 weeks; perforations not healing spontaneously

B. Paper Patch Myringoplasty (Fat Plug / Cigarette Paper Patch)

• Historical technique (Derlacki, 1953; later popularised by Rizer)
• Indication: Small, dry, central perforations in clinic setting
• Procedure:
  1. Edges freshened with a fine needle (de-epithelialisation)
  2. Phenol/TCA applied to edges
  3. Cigarette paper / Steri-strip / Gelfoam patch placed over defect
  4. Acts as scaffold for epithelial migration
• Success rate: 70–90% for perforations <30%

C. Fat Plug Myringoplasty (Ringenberg Technique)

• Indication: Small central perforations (<4 mm), office setting or minor OT
• Graft: Lobular fat from earlobe
• Technique: Fat plug placed through perforation using "dumbbell" technique — fat sits on both medial and lateral surfaces
• Advantages: Simple, quick, no hospital admission, high success rate (80–92%) for small perforations
• Hazarika (Textbook of ENT and Head & Neck Surgery): Advocates fat graft myringoplasty as first-line for small traumatic perforations

---

6.3 SURGICAL MANAGEMENT — MYRINGOPLASTY / TYMPANOPLASTY

When to Operate?

┌─────────────────────────────────────────────────────────────┐
│          INDICATIONS FOR SURGICAL REPAIR                    │
├─────────────────────────────────────────────────────────────┤
│  1. Perforation not healed after 3 months observation       │
│  2. Large perforation (>50% TM area)                        │
│  3. Blast/welding injuries (unlikely to heal spontaneously) │
│  4. Marginal perforation (cholesteatoma risk)               │
│  5. Associated ossicular disruption / discontinuity         │
│  6. Patient preference / professional needs (swimming etc.) │
│  7. Recurrent infections                                    │
│  8. Persistent conductive hearing loss                      │
├─────────────────────────────────────────────────────────────┤
│          CONTRAINDICATIONS                                  │
├─────────────────────────────────────────────────────────────┤
│  1. Active infection (operate after infection controlled)   │
│  2. Only hearing ear (relative contraindication)            │
│  3. Poor Eustachian tube function                           │
│  4. Unfit for anaesthesia                                   │
│  5. Children <4–5 years (Eustachian tube immature)         │
└─────────────────────────────────────────────────────────────┘

---

Wullstein Classification of Tympanoplasty (1956)

---

Surgical Approaches

┌─────────────────────────────────────────────────────┐
│         SURGICAL APPROACH DECISION TREE             │
├─────────────────────────────────────────────────────┤
│                                                     │
│  Perforation size?                                  │
│       │                                             │
│  Small/Medium          Large/Total                  │
│       │                      │                     │
│  Transcanal approach    Postauricular / Endaural    │
│  (if good EAC access)   approach                   │
│                                                     │
│  Microscope vs Endoscope?                           │
│  • Endoscopic: better visualisation, no incision   │
│  • Microscopic: traditional, better bimanual        │
│                                                     │
└─────────────────────────────────────────────────────┘

---

Graft Materials

┌────────────────────────────────────────────────────────────────┐
│                   GRAFT MATERIALS COMPARISON                   │
├───────────────────┬────────────────┬───────────────────────────┤
│  GRAFT            │ TAKE RATE      │  NOTES                    │
├───────────────────┼────────────────┼───────────────────────────┤
│ Temporalis fascia │ 85–95%         │ GOLD STANDARD — fibrous,  │
│ (TF)              │                │ strong, easily harvested  │
├───────────────────┼────────────────┼───────────────────────────┤
│ Perichondrium     │ 85–92%         │ Good for atelectatic TM,  │
│ (Tragal/conchal)  │                │ stiffer, no retraction    │
├───────────────────┼────────────────┼───────────────────────────┤
│ Cartilage +       │ 90–97%         │ Best for revision, tube   │
│ Perichondrium     │                │ otitis, poor ET function  │
├───────────────────┼────────────────┼───────────────────────────┤
│ Fat (lobule)      │ 75–90%*        │ Office use, small defects │
├───────────────────┼────────────────┼───────────────────────────┤
│ Vein graft        │ 70–85%         │ Historical, rarely used   │
├───────────────────┼────────────────┼───────────────────────────┤
│ Allografts        │ Variable       │ Donor TM — largely         │
│                   │                │ abandoned (infection risk) │
├───────────────────┼────────────────┼───────────────────────────┤
│ Synthetic         │ 80–85%         │ Biodesign, AlloDerm —     │
│ (acellular)       │                │ RECENT ADVANCE            │
└───────────────────┴────────────────┴───────────────────────────┘
*For small perforations only

---

Graft Placement Techniques

┌───────────────────────────────────────────────────────────────────┐
│                   UNDERLAY vs OVERLAY TECHNIQUE                   │
├──────────────────────────┬────────────────────────────────────────┤
│        UNDERLAY          │            OVERLAY                     │
├──────────────────────────┼────────────────────────────────────────┤
│ Graft placed MEDIAL to   │ Graft placed LATERAL to TM remnant    │
│ TM remnant and handle    │ and handle of malleus                  │
│ of malleus               │                                        │
├──────────────────────────┼────────────────────────────────────────┤
│ Advantages:              │ Advantages:                            │
│ • Technically easier     │ • Better for anterior perforations    │
│ • Less blunting          │ • Good visualisation of graft         │
│ • Less lateralization    │                                        │
├──────────────────────────┼────────────────────────────────────────┤
│ Disadvantages:           │ Disadvantages:                         │
│ • Anterior visibility ↓  │ • Lateralization risk                 │
│ • Medialisation possible │ • Blunting of anterior sulcus         │
├──────────────────────────┼────────────────────────────────────────┤
│ Used by: Most surgeons   │ Used by: Selected cases               │
│ (Scott-Brown, Cummings)  │ (large anterior perforations)         │
└──────────────────────────┴────────────────────────────────────────┘

---

Step-by-Step Operative Technique: Postauricular Underlay Myringoplasty

STEP 1: Anaesthesia + Patient Positioning
  └── GA (preferred) or LA with sedation
  └── Head turned to opposite side, ear up
  └── Subperiosteal infiltration (1:100,000 adrenaline)
  └── Operating microscope / Endoscope setup

STEP 2: Incision
  └── Postauricular incision (Wilde's) 5 mm behind post. auricular fold
  └── Down to temporalis fascia

STEP 3: Graft Harvest
  └── Temporalis fascia harvested (2×2 cm)
  └── Dried on Teflon block (10–15 min)
  └── Pressed thin — semitransparent sheet

STEP 4: Exposure of EAC
  └── Postauricular flap elevated
  └── Soft tissue from EAC posterior wall cleared
  └── Ear speculum placed / posterior meatal skin elevated

STEP 5: Perforation Management
  └── Edges of perforation freshened / de-epithelialised
  └── 360° marginal strip removed with Rosen's needle
  └── Tympanomeatal flap elevated (if needed)
  └── Middle ear inspected — assess ossicles, mucosa

STEP 6: Graft Placement (Underlay technique)
  └── Graft slid MEDIAL to TM remnant
  └── Supported medially with Gelfoam packing
  └── Graft draped over handle of malleus
  └── Anterior flap repositioned
  └── Graft edges checked — no folding

STEP 7: Closure
  └── Gelfoam in EAC over graft
  └── Pope wick / ribbon gauze
  └── Postauricular wound closed in layers
  └── Mastoid dressing applied

---

6.4 MANAGEMENT OF ASSOCIATED INJURIES

A. Ossicular Chain Disruption

• Commonest: Incudostapedial joint dislocation (Stell & Maran, 5th Ed.)
• Incus dislocation: Most common ossicular injury in temporal bone trauma (Bailey & Love, 28th Ed., p. 777: "With severe head trauma the incus can be displaced, which leads to a conductive hearing loss")
• Assessment: PTA showing >40 dB ABG, tympanometry Type Ad (Jerger)
• Management:
  • Type II tympanoplasty: Ossiculoplasty — PORP / TORP (partial/total ossicular replacement prosthesis)
  • Materials: Hydroxyapatite, titanium, Plastipore
  • Timing: Can be staged — TM repair first, ossiculoplasty 6–12 months later

┌────────────────────────────────────────────────────────────┐
│        OSSICULAR INJURIES IN TEMPORAL BONE TRAUMA          │
├───────────────────────┬────────────────────────────────────┤
│  INJURY               │  TREATMENT                         │
├───────────────────────┼────────────────────────────────────┤
│ Incudostapedial        │ Reposition / PORP                  │
│ joint dislocation      │                                    │
├───────────────────────┼────────────────────────────────────┤
│ Incus dislocation     │ Reposition or remove; PORP/TORP    │
├───────────────────────┼────────────────────────────────────┤
│ Malleus fracture      │ Ossiculoplasty                     │
├───────────────────────┼────────────────────────────────────┤
│ Stapes fracture/      │ Stapedectomy / TORP                │
│ luxation              │                                    │
├───────────────────────┼────────────────────────────────────┤
│ Stapedial tendon      │ No specific treatment              │
│ disruption            │                                    │
└───────────────────────┴────────────────────────────────────┘

B. Perilymphatic Fistula (PLF)

• Mechanism: Blast overpressure → rupture of round/oval window membranes
• Features: Sensorineural hearing loss + vertigo after barotrauma
• Management:
  • Conservative: Strict bed rest, head elevation 30°, stool softeners, avoid Valsalva (4–6 weeks)
  • Surgical: Exploratory tympanotomy + fat/fascia patch to oval/round window if no improvement in 4–6 weeks

C. Inner Ear Concussion

• No membrane rupture, but cochlear/labyrinthine injury from pressure wave
• Features: SNHL, tinnitus, vertigo
• Management: Systemic corticosteroids (Prednisolone 1 mg/kg/day × 10 days), hyperbaric oxygen (emerging evidence)

D. Temporal Bone Fracture

• Longitudinal: 80% — follows EAC line; TM tear, blood in EAC, conductive HL; rare facial nerve palsy
• Transverse: 20% — crosses cochlea/labyrinth; profound SNHL, vertigo, facial palsy (50%)
• Management: HRCT temporal bone; neurosurgical consult; facial nerve decompression if paralysis complete + electrical evidence of degeneration (ENoG <10% at 72 hours — Cummings Otolaryngology, 7th Ed.)

---

6.5 SPECIAL SCENARIOS

Blast Injury / Explosive Injury

┌──────────────────────────────────────────────────────────────┐
│              BLAST INJURY MANAGEMENT PROTOCOL                │
├──────────────────────────────────────────────────────────────┤
│  Primary blast wave → TM perforation + ossicular injury      │
│  Secondary → shrapnel injury, penetrating trauma             │
│  Tertiary → impact injury from body displacement            │
│                                                              │
│  Management:                                                 │
│  • All blast victims → PTA assessment                        │
│  • NO spontaneous healing expected                           │
│  • HRCT temporal bone (both sides)                          │
│  • High-dose steroids if SNHL component                     │
│  • Surgical repair at 3 months if not healed               │
│  • Monitor for delayed perilymph fistula                    │
│  • Tympanoplasty results good (80–90% closure rate)         │
└──────────────────────────────────────────────────────────────┘

Welding Spark Injuries

• Molten metal droplet burns through TM
• Edges are thermally cauterised → will not heal spontaneously
• Metal fragment may lodge in middle ear → HRCT mandatory
• Surgical removal of metal + myringoplasty required
• Risk of chronic suppurative otitis media if untreated

Paediatric Traumatic Perforation

• Zakir Hussain (ENT for Undergraduates): Most heal spontaneously even without treatment
• Management similar; surgical repair deferred until age 5–7 years due to:
  • Immature Eustachian tube function
  • Frequent upper respiratory infections
  • Compliance issues
• Success rates of myringoplasty in children: 80–85% (comparable to adults when >7 years)

---

7. POSTOPERATIVE CARE AND FOLLOW-UP

IMMEDIATE (0–2 weeks):
  • Mastoid dressing removed at 48 hours
  • Systemic antibiotics × 5–7 days
  • Analgesics
  • Strict dry ear precautions
  • No nose blowing, no sneezing with mouth closed
  • Pope wick removed at 2 weeks

SHORT-TERM (2–6 weeks):
  • Ear canal packing/Gelfoam dissolves
  • Otoscopy — graft take assessment
  • PTA at 6 weeks

MEDIUM-TERM (3–6 months):
  • PTA at 3 months — ABG closure
  • Graft viability assessment
  • Evaluate for residual perforation

LONG-TERM:
  • Annual audiometry if associated SNHL
  • Monitor for cholesteatoma (marginal perforations)

---

8. COMPLICATIONS

8.1 Complications of Traumatic Perforation (Untreated)

8.2 Complications of Myringoplasty

INTRAOPERATIVE:
  • Chorda tympani nerve injury → taste disturbance (ageusia)
  • Ossicular injury
  • Carotid artery injury (rare, aberrant)
  • Perilymph fistula (iatrogenic)
  • Facial nerve injury (rare)

EARLY POSTOPERATIVE:
  • Graft failure / displacement
  • Haematoma
  • Wound infection
  • SNHL (rare)

LATE POSTOPERATIVE:
  • Residual/recurrent perforation (5–15%)
  • Graft lateralisation
  • Blunting of anterior sulcus
  • Tympanosclerosis
  • Retraction pocket
  • Cholesteatoma
  • Adhesive otitis media

---

9. PROGNOSIS AND OUTCOMES

---

10. RECENT ADVANCES

A. Endoscopic Ear Surgery (EES)

• Endoscopic myringoplasty: Introduced widely since 2010s
• Single-hand technique using 3 mm 0°/30°/45° Hopkins rod endoscopes
• Advantages: Panoramic view, no postauricular incision, day care, better anterior angle visualisation, less morbidity
• Outcomes: Comparable to microscopic (graft take 85–92%) — Tarabichi, Preyer studies
• Learning curve: Initially longer; now standard of care in many centres

B. Novel Scaffold Materials

• Acellular collagen matrix (Biodesign, Cook Medical): Xenograft scaffold — promotes regenerative healing
• Porous collagen membrane: As shown in experimental flowchart (PMC study) — applied to both acute and chronic perforations; promotes regenerative healing, reduces scar formation
• Amniotic membrane graft: Rich in growth factors (EGF, TGF-β); promotes epithelial regeneration; 85–90% success reported
• AlloDerm (acellular dermal matrix): Success rate 82–88%

C. Growth Factor Therapies

• Epidermal Growth Factor (EGF): Topical application to perforation edges promotes epithelial migration — Phase II/III trials ongoing
• Basic Fibroblast Growth Factor (bFGF): Stimulates fibrous layer regeneration; Spraying onto small perforations → 80% closure rate (Japanese studies — Hakuba et al.)
• Platelet-Rich Plasma (PRP): Autologous growth factor cocktail applied as scaffold; enhances graft take in myringoplasty

D. Biomaterial Patches

• Silk fibroin scaffold: Biodegradable, supports cell migration, promotes native-like TM healing
• Eardrum regeneration technology (Ear Science Institute Australia, 2016): "Bioscaffold" (non-expanded polytetrafluoroethylene + growth factors) placed in 30-minute office procedure — 100% closure in pilot study (Froehlich et al., 2016, JAMA Otolaryngol)

E. Laser-Assisted Myringoplasty

• CO₂ laser used for edge preparation and welding of fat/fascia graft — precise, bloodless, minimal thermal spread
• Useful in office-based procedures

F. Tissue Engineering

• Stem cell-seeded scaffolds: Mesenchymal stem cells applied on collagen membrane — in vitro studies showing trilaminar TM reconstruction
• 3D-bioprinted TM: Experimental; exact replication of trilaminar structure in animal models

G. Minimally Invasive Tympanotomy

• Robotics-assisted myringoplasty — emerging (Cochlear Ltd, HEARO system); submillimetre precision, reduced human tremor

H. Hyperbaric Oxygen Therapy (HBOT)

• Adjunct for blast-related inner ear injury (PLF, SNHL)
• 20 sessions at 2.4 ATA — evidence for improved SNHL outcomes within 3 months of injury

---

11. COMPLETE MANAGEMENT ALGORITHM — INTEGRATED FLOWCHART

┌─────────────────────────────────────────────────────────────────────────┐
│           COMPREHENSIVE MANAGEMENT OF TRAUMATIC TM PERFORATION          │
└─────────────────────────────────────────────────────────────────────────┘
                                    │
                            HISTORY + ETIOLOGY
                         (Slap/Blast/Welding/Instrument)
                                    │
                        ┌───────────▼────────────┐
                        │   CLINICAL ASSESSMENT  │
                        │  Otoscopy + PTA +       │
                        │  Tympanometry           │
                        └───────────┬────────────┘
                                    │
              ┌─────────────────────▼──────────────────────┐
              │           ASSOCIATED FEATURES?              │
              ├────────────────┬───────────────────────────-┤
              │   YES           │          NO               │
              ▼                │                            │
  ┌────────────────────┐       │                            │
  │ SNHL + Vertigo?    │       │                            │
  │ → PLF? HBOT/Rest   │       │                            │
  │ → Cochlear concus. │       │                            │
  │   Steroids         │       │                            │
  ├────────────────────┤       │                            │
  │ Facial Palsy?      │       │                            │
  │ → HRCT + ENoG      │       ▼                            │
  │ → Decompression    │  ┌────────────────────────────┐    │
  ├────────────────────┤  │  CONSERVATIVE MANAGEMENT   │    │
  │ Temporal Bone Fx?  │  │  • Keep ear dry             │    │
  │ → HRCT + Neurosurg │  │  • Systemic antibiotics     │    │
  ├────────────────────┤  │  • No aminoglycoside drops  │    │
  │ Ossicular disrupt? │  │  • Review at 6 weeks        │    │
  │ → HRCT + Ossiculop │  └──────────────┬─────────────┘    │
  └────────────────────┘                 │                   │
                                         ▼                   │
                              ┌──────────────────────┐       │
                              │  Healed at 3 months? │◄──────┘
                              └──────┬───────┬───────┘
                                    YES      NO
                                     ▼        ▼
                              ┌─────────┐  ┌─────────────────────────────┐
                              │DISCHARGE│  │   SURGICAL MANAGEMENT        │
                              │+ PTA    │  ├─────────────────────────────┤
                              └─────────┘  │ SMALL (<4mm):               │
                                           │ • Fat plug / Paper patch     │
                                           │ • Office procedure           │
                                           ├─────────────────────────────┤
                                           │ MEDIUM/LARGE:               │
                                           │ • Myringoplasty (Type I)     │
                                           │ • Underlay/overlay TF graft  │
                                           │ • Transcanal/Postauricular   │
                                           │ • Endoscopic (recent advance)│
                                           ├─────────────────────────────┤
                                           │ WITH OSSICULAR INJURY:       │
                                           │ • Type II/III Tympanoplasty  │
                                           │ • PORP/TORP                  │
                                           ├─────────────────────────────┤
                                           │ POSTOP FOLLOW-UP:            │
                                           │ • Otoscopy at 6 weeks        │
                                           │ • PTA at 3 months            │
                                           │ • Success: >90%              │
                                           └─────────────────────────────┘

---

12. CLINICAL IMAGES

Tympanic Membrane with Central Perforation (Otoscopic View)

Experimental Model: Collagen Membrane Graft for TM Repair (Recent Advance)

---

13. SUMMARY TABLE — MANAGEMENT AT A GLANCE

---

REFERENCES

1. Scott-Brown's Otolaryngology, Head & Neck Surgery, 8th Edition — Chapter on Otitis Media and TM perforations
2. Cummings Otolaryngology — Head and Neck Surgery, 7th Edition — Temporal Bone Trauma, Tympanoplasty
3. Stell and Maran's Textbook of Head and Neck Surgery and Oncology, 5th Edition — Ossicular chain disruption in trauma
4. Zakir Hussain — ENT for Undergraduates — Conservative management, myringoplasty indications
5. Dhingra PL — Diseases of Ear, Nose and Throat, 8th Edition — Classification, etiology, surgical management
6. Hazarika P — Textbook of ENT and Head & Neck Surgery — Fat graft myringoplasty, endoscopic repair
7. Bailey & Love's Short Practice of Surgery, 28th Edition, p. 777 — Spontaneous healing, surgical repair
8. Harrison's Principles of Internal Medicine, 21st Edition, p. 1023 — Tympanoplasty success rates
9. Wullstein H (1956) — Original tympanoplasty classification
10. Derlacki EL (1953) — Paper patch myringoplasty
11. Froehlich P et al. (2016) — JAMA Otolaryngology: Bioscaffold TM regeneration
12. Hakuba N et al. — bFGF topical application for TM closure
13. Tarabichi M — Endoscopic myringoplasty series
14. Eavey RD (1998) — Inlay butterfly myringoplasty

---

Key Teaching Points for 50-Mark Answer:

• 85–90% of traumatic TM perforations heal spontaneously within 3 months — watchful waiting is primary management
• Blast and welding injuries do not heal spontaneously — surgical repair is mandatory
• Myringoplasty (Tympanoplasty Type I) with temporalis fascia underlay is the gold standard
• Always rule out inner ear injury (PLF, cochlear concussion) and ossicular disruption
• Endoscopic ear surgery and bioactive scaffolds represent the forefront of modern management
• Success rates exceed 90% for tympanoplasty in experienced hands

---

DIFFERENTIAL DIAGNOSIS OF FLESHY MASS IN THE EXTERNAL EAR AND ITS MANAGEMENT

Comprehensive 50-Mark Answer

(Scott-Brown | Cummings | Stell & Maran | Zakir Hussain | Dhingra | Hazarika | Recent Advances)

---

1. INTRODUCTION

---

2. APPLIED ANATOMY OF THE EXTERNAL EAR

┌────────────────────────────────────────────────────────────────┐
│                  EXTERNAL EAR — ANATOMY                        │
│                                                                │
│  AURICLE (Pinna):                                              │
│  • Elastic cartilage (except lobule — fibrofatty)              │
│  • Skin: Tightly adherent anterolaterally                      │
│            Loose posteriorly (allows lesion expansion)         │
│  • Perichondrium: Avascular plane for haematomas               │
│  • Lymphatics → Preauricular, postauricular,                   │
│    upper deep cervical nodes                                   │
│                                                                │
│  EXTERNAL AUDITORY CANAL (EAC):                                │
│  • Length: ~24 mm                                              │
│  • Outer 1/3: Cartilaginous (skin with hair follicles,         │
│    sebaceous glands, ceruminous glands — source of tumours)    │
│  • Inner 2/3: Bony (thin keratinising squamous epithelium)     │
│  • Narrowest point: Isthmus (junction of bony & cart. EAC)    │
│  • Blood supply: Superficial temporal, posterior auricular,    │
│    deep auricular arteries                                     │
│  • Nerve supply: Auriculotemporal (V3), Arnold's (X),          │
│    Great auricular (C2,3), Facial nerve (VII — small area)     │
└────────────────────────────────────────────────────────────────┘

---

3. CLASSIFICATION OF FLESHY MASSES IN THE EXTERNAL EAR

┌─────────────────────────────────────────────────────────────────────┐
│           CLASSIFICATION OF FLESHY MASSES — EXTERNAL EAR            │
├────────────────────────┬────────────────────────────────────────────┤
│  INFLAMMATORY /        │  NEOPLASTIC                                │
│  NON-NEOPLASTIC        │                                            │
├────────────────────────┼────────────────────────────────────────────┤
│ 1. Aural Polyp         │  BENIGN:                                   │
│ 2. Granulation tissue  │  1. Osteoma / Exostosis                    │
│ 3. Malignant otitis    │  2. Fibroma                                │
│    externa (MOE)       │  3. Papilloma (Squamous)                   │
│ 4. Keratosis           │  4. Keloid / Hypertrophic scar             │
│    obturans            │  5. Haemangioma                            │
│ 5. Cholesteatoma       │  6. Ceruminoma (benign)                    │
│    (primary EAC)       │  7. Pleomorphic adenoma                    │
│ 6. Haematoma auris     │  8. Sebaceous cyst (infected)              │
│ 7. Keloid              │  9. Chondrodermatitis nodularis            │
│ 8. Reactive lymph node │ 10. Gouty tophi                           │
│    (preauricular)      │                                            │
├────────────────────────┼────────────────────────────────────────────┤
│                        │  MALIGNANT:                                │
│                        │  1. Squamous Cell Carcinoma (SCC) — MOST  │
│                        │     COMMON malignancy of EAC              │
│                        │  2. Basal Cell Carcinoma (BCC) — MOST     │
│                        │     COMMON malignancy of auricle          │
│                        │  3. Adenoid Cystic Carcinoma               │
│                        │  4. Ceruminous Adenocarcinoma              │
│                        │  5. Melanoma                               │
│                        │  6. Rhabdomyosarcoma (paediatric)          │
│                        │  7. Metastatic deposits                    │
└────────────────────────┴────────────────────────────────────────────┘

---

4. DETAILED DIFFERENTIAL DIAGNOSIS

---

4.1 AURAL POLYP (MOST IMPORTANT)

Chronic infection / CSOM
       ↓
Mucosal oedema + granulation tissue
       ↓
Polypoidal change → protrudes through TM perforation
       ↓
AURAL POLYP in EAC

• Appearance: Pink/red/pale fleshy mass in EAC, bleeds on touch
• Symptoms: Otorrhoea (mucoid/mucopurulent), conductive hearing loss, otalgia
• Key Sign (Harrison's, p. 1023): "The presence of an aural polyp obscuring the tympanic membrane is highly suggestive of an underlying cholesteatoma"
• Probing reveals the pedicle through TM perforation

---

4.2 CHOLESTEATOMA (EAC / MIDDLE EAR)

1. Primary acquired (middle ear) — retraction pocket; presents as aural polyp through perforation
2. EAC cholesteatoma (primary EAC) — rare; arises from EAC skin directly, no middle ear involvement
3. Congenital — white pearly mass behind intact TM

• Pearly white debris visible behind polyp
• Attic (superior) origin — pars flaccida perforation
• Bone erosion on CT
• Foul-smelling discharge
• Conductive HL (ossicular erosion)

---

4.3 MALIGNANT OTITIS EXTERNA (MOE)

• Granulation tissue at bony-cartilaginous junction of EAC floor — pathognomonic sign
• Tissue is pale/red, friable, bleeds easily
• Must be biopsied to exclude carcinoma (Cummings Otolaryngology, 7th Ed.)

• Elderly diabetic patient
• Severe unremitting otalgia (out of proportion to findings)
• Cranial nerve palsies (VII, IX, X, XI, XII — as infection spreads)
• Technetium bone scan / Gallium scan positive

---

4.4 KERATOSIS OBTURANS vs EAC CHOLESTEATOMA

---

4.5 OSTEOMA / EXOSTOSIS

• Multiple, bilateral, broad-based bony swellings in bony EAC
• "Surfer's ear" — caused by repeated cold water/wind exposure
• Covered by normal thin skin — NOT fleshy but can appear as pale mass
• Gradual conductive hearing loss / recurrent OE

• Solitary, pedunculated, unilateral
• Arises from tympanosquamous or tympanomastoid suture line
• Smooth, bony-hard, skin-covered
• Treatment: Surgical removal (canaloplasty) if symptomatic

---

4.6 BENIGN TUMOURS OF EAC AND AURICLE

Papilloma

• Most common benign tumour of EAC (Scott-Brown, 8th Ed.)
• HPV-associated (types 6, 11)
• Wart-like, cauliflower surface, skin-coloured/pale
• Rarely bleeds
• Management: Surgical excision; CO₂ laser ablation

Ceruminoma (Ceruminous Adenoma)

• Arises from ceruminous glands in outer 1/3 EAC
• Slow-growing, firm, fleshy nodule
• Malignant variant: Ceruminous adenocarcinoma
• Management: Wide local excision; sleeve resection of EAC

Haemangioma

• Soft, compressible, blue/purple-red vascular lesion
• Blanches on pressure
• Auricle or EAC
• Management: Observation (involute in children), propranolol, laser, or surgery

Keloid

• Hypertrophic scar tissue extending beyond wound margins
• Common at lobule post-ear piercing
• Management: Triamcinolone injections, surgical excision + radiation, silicone sheets

Sebaceous Cyst (Infected)

• Blocked pilosebaceous unit in EAC outer 1/3
• Becomes fleshy, tender when infected
• Management: I&D when acute; complete excision when resolved

Chondrodermatitis Nodularis Helicis

• Painful nodule on helix/antihelix
• Reactive dermal/cartilaginous degeneration
• Management: Collagenase, excision, wedge resection of cartilage

---

4.7 MALIGNANT TUMOURS

A. Squamous Cell Carcinoma (SCC) of EAC

• Fleshy, irregular, ulcerated mass in EAC
• Bleeds easily (contact bleeding)
• Unremitting otalgia (referred through auriculotemporal nerve)
• Otorrhoea — blood-stained
• Facial nerve palsy (advanced disease)
• Conductive hearing loss
• Preauricular/postauricular lymphadenopathy

T1: Tumour limited to EAC, no erosion
T2: Tumour with limited bone erosion (<0.5 cm)
     OR soft tissue involvement <0.5 cm
T3: Erosion of osseous EAC full thickness
     OR middle ear/mastoid involvement
     OR facial nerve palsy
T4: Tumour invades cochlea, petrous apex, dura,
     parotid, jugular foramen, TMJ, carotid

B. Basal Cell Carcinoma (BCC) of Auricle

• MOST COMMON malignancy of auricle (Dhingra, 8th Ed.)
• Sun-exposed areas (upper helix, antihelix)
• Pearly, rolled edges; telangiectasia; central ulceration ("rodent ulcer")
• Rarely metastasises
• Management: Mohs micrographic surgery; wide excision

C. Adenoid Cystic Carcinoma (ACC) / Ceruminous Adenocarcinoma

• Arises from ceruminous glands — EAC outer 1/3
• Perineural spread — hallmark feature; early facial nerve involvement
• Cribriform / tubular / solid patterns on histology
• "Skip lesions" along nerve — difficult to achieve clear margins
• Management: Radical temporal bone resection + adjuvant radiotherapy

D. Melanoma of Auricle

• Pigmented/amelanotic fleshy mass
• Rapidly growing, irregular
• Poor prognosis
• Management: Wide excision + SLN biopsy; immunotherapy for metastatic disease

E. Rhabdomyosarcoma (Paediatric)

• Most common malignant tumour of the ear in children (Hazarika, ENT & Head-Neck Surgery)
• Fleshy, rapidly growing, fills EAC
• Middle ear involvement common
• Management: Multimodal — chemotherapy (VAC: Vincristine/Actinomycin/Cyclophosphamide) + surgery + radiation

---

5. COMPARATIVE DIFFERENTIAL DIAGNOSIS TABLE

---

6. DIAGNOSTIC APPROACH

Clinical Assessment Algorithm

┌────────────────────────────────────────────────────────────────────┐
│        DIAGNOSTIC ALGORITHM — FLESHY MASS IN EXTERNAL EAR         │
└────────────────────────────────────────────────────────────────────┘
                              │
                    ┌─────────▼─────────┐
                    │  HISTORY TAKING   │
                    │  • Duration       │
                    │  • Pain character │
                    │  • Discharge type │
                    │  • Hearing loss   │
                    │  • Risk factors   │
                    │  • Age, DM, immune│
                    └─────────┬─────────┘
                              │
                    ┌─────────▼─────────┐
                    │   OTOSCOPY /      │
                    │ ENDOSCOPIC EXAM   │
                    │ • Site, size      │
                    │ • Surface, colour │
                    │ • Pedicle, depth  │
                    │ • TM visibility   │
                    │ • Bone exposure   │
                    └────────┬──────────┘
                             │
          ┌──────────────────▼──────────────────┐
          │           CHARACTER OF MASS          │
          └─┬──────────────┬─────────────┬───────┘
            │              │             │
   SOFT/FLESHY      HARD/BONY        PEARLY/WHITE
   Bleeds on        Bony hard         Cheesy debris
   touch            Skin covered      Attic origin
            │              │             │
            ▼              ▼             ▼
    Polyp/Granul/    Osteoma/       Cholesteatoma
    SCC/BCC/MOE      Exostosis
            │
     ┌──────▼──────┐
     │ ORIGIN?     │
     ├─────────────┤
     │ EAC floor   │→ MOE (if diabetic)
     │ TM/ME       │→ Aural polyp (CSOM)
     │ Attic area  │→ Cholesteatoma
     │ EAC wall    │→ SCC/Papilloma/Ceruminoma
     │ Auricle     │→ BCC/SCC/Melanoma/Keloid
     └─────────────┘
              │
    ┌──────────▼──────────┐
    │   INVESTIGATIONS    │
    └─────────────────────┘

---

Investigations

---

7. MANAGEMENT

OVERVIEW MANAGEMENT FLOWCHART

┌──────────────────────────────────────────────────────────────────────┐
│         MANAGEMENT ALGORITHM — FLESHY MASS IN EXTERNAL EAC           │
└──────────────────────────────────────────────────────────────────────┘
                                  │
                     CLINICAL ASSESSMENT + INVESTIGATIONS
                                  │
          ┌───────────────────────▼──────────────────────────┐
          │              BIOPSY ALL UNCERTAIN MASSES          │
          └───────────┬─────────────────────────┬────────────┘
                      │                         │
              INFLAMMATORY /              NEOPLASTIC
              NON-NEOPLASTIC                    │
                      │             ┌───────────┴───────────┐
          ┌───────────▼───────┐  BENIGN              MALIGNANT
          │  AURAL POLYP      │     │                      │
          │  GRANULATION      │  See Section 7.2       See Section 7.3
          │  KERATOSIS OBT.   │
          │  MOE              │
          └───────────┬───────┘
                      │
          ┌───────────▼───────────────────────┐
          │        NON-NEOPLASTIC MANAGEMENT   │
          └───────────────────────────────────┘

---

7.1 MANAGEMENT OF AURAL POLYP

AURAL POLYP DETECTED
        │
        ▼
   FIRST: BIOPSY (Rule out malignancy / granulomatous disease)
        │
        ▼
   MICROBIOLOGICAL SWAB + PTA + HRCT Temporal Bone
        │
        ▼
   ┌─────────────────────────────────────────────┐
   │  MEDICAL MANAGEMENT (initial 4–6 weeks)     │
   │  • Topical: Ciprofloxacin ear drops          │
   │  • Systemic: Amoxicillin-clavulanate / FQ   │
   │  • Topical steroid-antibiotic drops          │
   │  • Aural toilet (suction clearance)          │
   └──────────────────┬──────────────────────────┘
                      │
              Polyp resolved?
                 │         │
                YES         NO
                 │          │
         Treat CSOM     SURGICAL REMOVAL
         (underlying)   of polyp
                        │
              ┌─────────▼────────────────────┐
              │  POLYPECTOMY TECHNIQUE        │
              │  • Suction under microscope   │
              │  • Snare/avulsion carefully   │
              │  • DO NOT AVULSE forcefully   │
              │    (risk: ossicular damage,   │
              │     facial nerve injury)      │
              └─────────┬────────────────────┘
                        │
                        ▼
              ┌─────────────────────────────┐
              │   TREAT UNDERLYING CAUSE    │
              ├─────────────────────────────┤
              │ Safe CSOM → Modified        │
              │ radical/cortical mastoid    │
              │ + tympanoplasty             │
              │                             │
              │ Unsafe CSOM/Cholesteatoma   │
              │ → Radical/Canal wall down   │
              │   mastoidectomy             │
              └─────────────────────────────┘

---

7.2 MANAGEMENT OF MALIGNANT OTITIS EXTERNA (MOE)

DIAGNOSIS OF MOE CONFIRMED
(Elderly diabetic + granulation EAC floor + unremitting pain + Pseudomonas)
              │
              ▼
        INVESTIGATIONS:
        • RBS / HbA1c → Control diabetes (KEY)
        • HRCT Temporal bone (bony erosion extent)
        • MRI (dural/soft tissue involvement)
        • Tc-99 bone scan (active disease)
        • Ga-67 scan (treatment response)
        • Facial nerve testing (ENoG if palsy)
              │
              ▼
        MEDICAL MANAGEMENT (4–6 weeks minimum)
        ┌──────────────────────────────────────┐
        │  Antipseudomonal antibiotics:         │
        │  • IV Piperacillin-tazobactam OR      │
        │    IV Ceftazidime × 4–6 weeks        │
        │  • ORAL: Ciprofloxacin 750 mg BD      │
        │    (excellent bone penetration)       │
        │  • Duration: Until Gallium scan −ve   │
        │    (typically 6–12 weeks)             │
        │  Diabetic control (HbA1c <7%)         │
        │  Aural toilet + topical antibiotics   │
        │  Hyperbaric oxygen therapy (adjunct)  │
        └──────────────────────────────────────┘
              │
              ▼
        SURGICAL ROLE (limited):
        • Debridement of necrotic tissue
        • Biopsy to exclude SCC
        • Sequestrum removal
        • NOT radical surgery (ineffective)

---

7.3 MANAGEMENT OF BENIGN NEOPLASMS

---

7.4 MANAGEMENT OF MALIGNANT TUMOURS

A. Squamous Cell Carcinoma of EAC — Detailed Protocol

┌──────────────────────────────────────────────────────────────────────┐
│              SCC EAC — STAGING AND TREATMENT PROTOCOL                │
│                    (Pittsburgh TNM Staging)                          │
└──────────────────────────────────────────────────────────────────────┘

T1 (EAC confined, no erosion)
    │
    ▼
LATERAL TEMPORAL BONE RESECTION (LTBR)
    • En bloc resection: EAC + TM + malleus + incus
    • Parotidectomy (superficial) if parotid involved
    • Neck dissection (N0: selective levels II-V)
    • Adjuvant radiotherapy (60–66 Gy)
    • 5-year survival: 80–95%

T2 (Limited bone erosion / soft tissue <0.5 cm)
    │
    ▼
LTBR + PAROTIDECTOMY + POST-OP RT
    • 5-year survival: 60–75%

T3 (Full thickness EAC erosion / middle ear / mastoid / CN VII)
    │
    ▼
SUBTOTAL TEMPORAL BONE RESECTION (STBR)
    • Includes: EAC + TM + mastoid + middle ear
    • Cochlea and labyrinth preserved if possible
    • Facial nerve: Sacrifice and cable graft if involved
    • Modified radical neck dissection
    • Adjuvant chemoradiation (cisplatin-based)
    • 5-year survival: 40–55%

T4 (Petrous apex, dura, carotid, parotid, TMJ, JF)
    │
    ▼
TOTAL TEMPORAL BONE RESECTION (TTBR)
    • Highly morbid; consider multidisciplinary
    • Neurosurgical input for dural/intracranial
    • Internal carotid artery sacrifice (balloon
      test occlusion first)
    • Palliative intent often
    • Adjuvant chemoradiotherapy
    • 5-year survival: 10–25%

STEP 1: Incision — Postauricular + extension to neck
STEP 2: Identify facial nerve at stylomastoid foramen
STEP 3: Parotidectomy (at least superficial)
STEP 4: Mastoidectomy — expose sigmoid sinus, dura
STEP 5: Divide EAC at isthmus (medial cut)
STEP 6: Divide TM attachment at annulus
STEP 7: Disarticulate incudomalleolar joint
STEP 8: En bloc specimen removal
STEP 9: Neck dissection
STEP 10: Reconstruction — STSG or free flap
STEP 11: Post-op: Adjuvant radiotherapy 60–66 Gy

B. Basal Cell Carcinoma (BCC) of Auricle

STAGING (AJCC 8th Edition — Non-melanoma skin cancer)
        │
        ▼
Small (<2 cm), well-defined:
    → Mohs Micrographic Surgery (MMS) — GOLD STANDARD
    → OR Wide local excision (5 mm margins)
    → 5-year cure rate: >95%

Large / ill-defined / periauricular:
    → MMS strongly preferred
    → Postauricular free flap / pedicle flap reconstruction
    → Radiation therapy (if inoperable or elderly)

Perineural invasion / bone involvement:
    → HRCT + MRI
    → Wide excision + radiation
    → Consider temporal bone surgery if EAC involved

C. Adenoid Cystic Carcinoma (ACC)

D. Melanoma of Auricle

Breslow thickness <1 mm:
    → Wide local excision (1 cm margins)
    → Sentinel lymph node biopsy (SLNB)

Breslow thickness >1 mm:
    → 2 cm margins
    → SLNB → completion node dissection if positive
    → Adjuvant immunotherapy (pembrolizumab, nivolumab)

Metastatic:
    → Immune checkpoint inhibitors (anti-PD1)
    → BRAF inhibitors (if BRAF V600E mutation)
    → 5-year survival: 15–20%

E. Rhabdomyosarcoma (Paediatric)

• Multimodal treatment (Hazarika, ENT & Head-Neck Surgery):
  • Chemotherapy: VAC protocol (Vincristine + Actinomycin-D + Cyclophosphamide)
  • Radiation therapy: 50.4 Gy
  • Surgery: Limited (complete excision if feasible without major morbidity)
  • IRS (Intergroup Rhabdomyosarcoma Study) Group system guides treatment
  • 5-year survival: Group I (60–80%), Group IV (<30%)

---

7.5 RECONSTRUCTION AFTER TEMPORAL BONE RESECTION

┌──────────────────────────────────────────────────────────────────┐
│             RECONSTRUCTIVE OPTIONS POST-TUMOUR EXCISION           │
├────────────────────────┬─────────────────────────────────────────┤
│  DEFECT                │  RECONSTRUCTION                         │
├────────────────────────┼─────────────────────────────────────────┤
│ Small EAC defect       │ STSG (split thickness skin graft)       │
├────────────────────────┼─────────────────────────────────────────┤
│ Auricular defect       │ Posterior auricular flap                │
│ (partial)              │ Antia-Buch chondrocutaneous advancement │
│                        │ Preauricular transposition flap         │
├────────────────────────┼─────────────────────────────────────────┤
│ Total auricle loss     │ Prosthetic ear (osseointegrated implant)│
│                        │ Rib cartilage reconstruction (Nagata)   │
├────────────────────────┼─────────────────────────────────────────┤
│ Temporal bone + skin   │ Pectoralis major pedicle flap           │
│ defect (large)         │ Free radial forearm flap (thin)         │
│                        │ Free anterolateral thigh flap           │
├────────────────────────┼─────────────────────────────────────────┤
│ Facial nerve sacrifice │ Primary end-to-end anastomosis          │
│                        │ Sural nerve cable graft                 │
│                        │ Hypoglossal-facial anastomosis          │
│                        │ Free muscle transfer (gracilis)         │
└────────────────────────┴─────────────────────────────────────────┘

---

8. RADIOTHERAPY IN EAC MALIGNANCY

---

9. RECENT ADVANCES

A. Endoscopic Ear Surgery (EES)

• Endoscopic polypectomy and EAC tumour excision with 3 mm 0°/30° Hopkins rod
• No postauricular incision; better visualisation of recesses
• Used for T1 EAC SCC — endoscopic lateral wall resection
• (Tarabichi, Thomassin-Naggara series, 2015–2022)

B. Molecular Targeted Therapy

• EGFR overexpression in EAC SCC → Cetuximab (anti-EGFR) as adjunct to chemoradiation
• HPV-positive oropharyngeal paradigm applied to HPV+ EAC papilloma/SCC — deescalation trials ongoing
• Nivolumab/Pembrolizumab (anti-PD1): Approved for recurrent/metastatic SCC head & neck — used in unresectable EAC SCC

C. Mohs Surgery for EAC Malignancy

• Expanding application of Mohs micrographic surgery to EAC SCC (T1/T2)
• 100% margin assessment; maximum tissue preservation
• 5-year local control >90% for T1 lesions

D. Proton Beam Therapy

• For skull base tumours (ACC, chordoma) in proximity to temporal bone
• Precise dose deposition (Bragg peak) — spares cochlea, brainstem
• (Mayo Clinic, Massachusetts General Hospital series)

E. Osseointegrated Auricular Prosthetics

• BAHA Attract/Connect system + titanium implants for auricular fixation
• 3D-printed individualised prostheses using patient CT data (mirroring technique)
• High patient satisfaction scores; alternative to rib cartilage reconstruction

F. Sentinel Lymph Node Biopsy (SLNB) in Auricular SCC/Melanoma

• Increasingly used for T2+ auricular SCC and all melanoma >1 mm
• Reduces unnecessary neck dissection
• Tc-99m nanocolloid + SPECT-CT for accurate mapping of auricular drainage

G. CAR-T Cell Therapy

• Experimental for recurrent EAC SCC and rhabdomyosarcoma
• Phase I/II trials showing response in recurrent head and neck SCC

H. AI-Assisted Otoscopy

• Deep learning algorithms (CNN-based) for automatic classification of EAC masses from endoscopic images
• Sensitivity >90% for aural polyp vs malignancy differentiation in validation studies

I. Photodynamic Therapy (PDT)

• For superficial EAC papilloma and early BCC
• 5-ALA photosensitiser + 630 nm laser
• Minimal morbidity; repeat treatments possible

---

10. COMPLICATIONS OF UNTREATED/MISMANAGED EAC MASSES

---

11. FOLLOW-UP PROTOCOL

MALIGNANT CONDITIONS:
  • 1st year: Every 4–6 weeks clinically + endoscopy
  • 2nd–5th year: 3-monthly
  • Beyond 5 years: 6-monthly (ACC: indefinitely)
  • MRI at 6 months post-treatment
  • PET-CT at 12 months (high-risk cases)
  • PTA at each visit (monitor cochlear function)

BENIGN/INFLAMMATORY:
  • Aural polyp post-tympanomastoid surgery:
    6 weeks, 3 months, 6 months, then annually
  • MOE: Gallium scan to confirm resolution
  • Keloid: 6-weekly for steroid injections

---

12. INTEGRATED SUMMARY FLOWCHART

┌─────────────────────────────────────────────────────────────────────────┐
│         COMPLETE MANAGEMENT — FLESHY MASS IN EXTERNAL EAR               │
└─────────────────────────────────────────────────────────────────────────┘
                                    │
                         HISTORY + CLINICAL EXAM
                         (Otoscopy/Endoscopy)
                                    │
                  ┌─────────────────▼──────────────────┐
                  │      MANDATORY: BIOPSY ALL           │
                  │      UNCERTAIN MASSES               │
                  └──────────────┬─────────────────────┘
                                 │
          ┌──────────────────────▼────────────────────────┐
          │                 HRCT TEMPORAL BONE             │
          │   (all except obvious superficial lesions)     │
          └───────┬──────────────────┬────────────────────┘
                  │                  │
          BONE EROSION        NO BONE EROSION
                  │                  │
             MRI TB          SOFT TISSUE LESION
                  │                  │
          Intracranial        Inflammatory / Benign
          extension?          Neoplastic
                  │
         ┌────────▼─────────────────────────────────────────┐
         │              FINAL DIAGNOSIS                       │
         ├──────────────────┬───────────────────────────────-┤
         │  INFLAMMATORY    │  BENIGN NEOPLASM │  MALIGNANT  │
         ├──────────────────┼──────────────────┼─────────────┤
         │ Aural Polyp:     │ Papilloma:       │ SCC EAC:    │
         │ Medical → Polyp  │ CO₂ laser/       │ LTBR/STBR + │
         │ removal → Master │ Excision         │ RT/Chemo    │
         │ oidectomy        │                  │             │
         │                  │ Osteoma:         │ BCC/SCC     │
         │ MOE:             │ Canaloplasty     │ Auricle:    │
         │ IV ABx + DM ctrl │                  │ Mohs/WLE    │
         │ + HBOT           │ Keloid:          │             │
         │                  │ Triamcinolone    │ ACC:        │
         │ Cholesteatoma:   │ + Excision +     │ Temporal    │
         │ CWD/CWU mast     │ RT               │ bone res.   │
         │ oidectomy        │                  │ + RT        │
         │                  │ Haemangioma:     │             │
         │                  │ Propranolol/     │ Melanoma:   │
         │                  │ Laser/Surgery    │ WLE + SLNB  │
         │                  │                  │ + Immuno Rx │
         │                  │                  │             │
         │                  │                  │ RMS (peds): │
         │                  │                  │ VAC Chemo   │
         │                  │                  │ + RT        │
         └──────────────────┴──────────────────┴─────────────┘
                                    │
                            RECONSTRUCTION
                    (STSG / Flap / Prosthetic ear)
                                    │
                            ADJUVANT THERAPY
                    (RT / Chemotherapy / Immunotherapy)
                                    │
                            FOLLOW-UP PROTOCOL

---

13. KEY TEACHING POINTS (SUMMARY)

---

REFERENCES

1. Harrison's Principles of Internal Medicine, 21st Edition, p. 1023 — Aural polyp, cholesteatoma, CSOM
2. Scott-Brown's Otolaryngology, Head & Neck Surgery, 8th Edition — EAC tumours, benign lesions, surgical techniques
3. Cummings Otolaryngology — Head & Neck Surgery, 7th Edition — Malignant otitis externa, EAC SCC, temporal bone surgery
4. Stell & Maran's Head & Neck Surgery, 5th Edition — Classification and staging of EAC malignancy
5. Dhingra PL — Diseases of ENT, 8th Edition — Aural polyp, cholesteatoma, differential diagnosis
6. Hazarika P — Textbook of ENT & Head-Neck Surgery — Rhabdomyosarcoma, aural polyp management
7. Zakir Hussain — ENT for Undergraduates — Conservative management of aural polyp, surgical indications
8. Bailey & Love's Short Practice of Surgery, 28th Edition — Trauma and middle ear disease
9. Pittsburgh TNM Staging System — Arriaga et al. (1990) — EAC SCC staging
10. Wullstein H (1956) — Tympanoplasty classification
11. Tarabichi M et al. — Endoscopic ear surgery for EAC lesions
12. Eby TL, Makielski KH — Ceruminous gland tumours
13. Chang CH et al. — Lateral temporal bone resection outcomes
14. IRS (Intergroup Rhabdomyosarcoma Study) Group — Paediatric rhabdomyosarcoma protocols
15. Mohs FE — Micrographic surgery technique